|
Affiliation |
Faculty of Medicine College Hospital Urology |
|
Title |
Assistant Professor |
|
External Link |
|
|
Related SDGs |
|
MURASHIMA Takaya
|
|
|
Papers 【 display / non-display 】
-
Abe J., Murashima T., Kojima S., Ueno T., Takei A., Nakai N., Akioka T., Kamoto T., Sawada A.
International Journal of Clinical Oncology 2026.2
Publishing type：Research paper (scientific journal) Publisher：International Journal of Clinical Oncology
Advances in immuno-oncology (IO)-based systemic therapies have improved treatment outcomes for patients with metastatic renal cell carcinoma (mRCC). However, long-term survival of these patients remains challenging, highlighting the need to reassess the role of local and metastasis-directed treatments. Cytoreductive nephrectomy (CN) has traditionally been a part of the therapeutic armamentarium for mRCC, and evidence from the targeted therapy era—most notably the CARMENA and SURTIME trials—indicates that deferred CN after initial systemic therapy may benefit carefully selected patients. In the IO era, prospective evidence regarding CN is lacking, although ongoing trials, such as NORDIC-SUN and PROBE, are expected to refine patient selection and optimal timing. Real-world analysis reveals a significant decline in conducting CN since 2018. However, CN remains associated with improved overall survival of patients who received several IO-based first-line regimens after adjustment for baseline characteristics. Metastasis-directed treatments, including metastasectomy and local interventions for bone metastases, continue to exhibit potential survival benefits and may maintain functional status when complete resection of lesions is achievable. Considering the absence of definitive prospective data applicable to routine clinical practice, individualized treatment strategies should consider CN and local therapies alongside systemic treatment response, tumor biology, and patient-specific prognostic factors.
-
HIDA Takuya, FUJITA Naoko, MURASHIMA Takaya, FUJII Masato, NAGAI Takahiro, ONIZUKA Chie, NISHIMOTO Koshiro, SAWADA Atsuro, MUKAI Shoichiro, KAMOTO Toshiyuki
71 ( 6 ) 191 - 195 2025.6
Language：Japanese Publishing type：Research paper (scientific journal)
-
村嶋 隆哉, 藤井 将人, 永井 崇敬, 向井 尚一郎, 賀本 敏行
Journal of Medical Case Reports 19 118 2025.3
Language：English Publishing type：Research paper (scientific journal) Publisher：Springer Science and Business Media LLC
Introduction
Mixed sex cord stromal tumor is defined as a tumor consisting of various combinations of sex cord stromal elements, and the tumor is extremely rare.
Case presentation
A 76-year-old Japanese male visited our hospital complaining of left scrotal swelling. Magnetic resonance imaging of the mass showed a multilocular cystic pattern with different degrees of intensities in each cyst. The solid component was observed in part showing hypointensity on the T2-weighted image. Although there was no apparent evidence of malignancy in cytology of punctured fluid of the cystic tumor, malignant potential was not ruled out completely. Therefore, transinguinal radical orchiectomy was performed, and the tumor was diagnosed as mixed sex cord stromal tumor consisting of adult-type granulosa cell tumor, Leydig cell tumor and Sertoli cell tumor components. The patient recovered without any postoperative event. In addition, neither apparent recurrence nor metastasis was observed at 7 years after surgery.
Conclusion
The tumor showed a multilocular cystic appearance with solid component, which was similar in appearance to previous reports of the same pathological features. Pathological findings of each component were compatible with those of mixed sex cord stromal tumor, and immunohistochemical analysis was useful for accurate diagnosis. The tumor was successfully resected, and no apparent recurrence was observed at 7 years after surgery. -
Paratesticular cellular angiofibroma: a case report Reviewed
18 ( 1 ) 170 2024.4
Authorship：Lead author Language：English Publishing type：Case report